Karsten Fischer is a seasoned manager with more than 20 years of experience in the field of biotechnology. In his last position as CEO of Memo Therapeutics AG, he developed the company from the laboratory bench to a late-stage biotechnology company with a pivotal clinical phase II/III study in the US and a partnership with Ono Pharmaceutical Co., Ltd.
After training in biochemistry and completing his doctorate at the Max Planck Institute for Biochemistry and Colorado State University, he started his career at a subsidiary of Deutsche Bank, Deutsche Venture Capital. There he was responsible for analyzing biotechnology companies for equity investment. He then worked at McKinsey&Co, Sanofi SA and WestLB, where he led the Equity Capital Markets team in the Life Sciences & Chemicals division. In the next step, he moved to BioMedPartners AG as a partner, where he was responsible for a large number of investments in the biotech sector. As investment banker, investor and CEO, he was responsible for financing events of over USD 500m as well as numerous M&A transactions.
